Compare AU
Compare CURE vs. QSML
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the S&P US Biotech (CURE) and the MSCI World Small Cap Quality 150 (ex AUS) (QSML). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | QSML | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 81 | 94 |
Median incremental investment | $620.00 | $1,000.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,413.72 | $4,907.20 |
Average age group | > 35 | > 35 |
Key Summary
CURE | QSML | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | QSML.AX was created on 2021-03-08 by VanEck. The fund's investment portfolio concentrates primarily on small cap equity. The Fund gives investors a diversified portfolio of 150 international developed market small-cap quality growth companies having durable business models and sustainable competitive advantages. |
Top 3 holdings | Moderna Inc (2.59 %) Neurocrine Biosciences Inc (2.50 %) AbbVie Inc (2.40 %) | Comfort Systems USA Inc (1.72 %) Casey's General Stores Inc (1.35 %) Curtiss-Wright Corp (1.25 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Industrials (52.02 %) Financials (27.52 %) Other (21.00 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | United States (81.64 %) United Kingdom of Great Britain and Northern Ireland (8.09 %) Japan (2.80 %) |
Management fee | 0.45 % | 0.59 % |
Key Summary
CURE | QSML | |
|---|---|---|
Issuer | Global X | VanEck |
Tracking index | S&P Biotechnology Select Industry | MSCI World ex Australia Small Cap Quality 150 Index - AUD - Benchmark TR Net |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.59 % |
Price | $48.94 | $30.43 |
Size | $36.961 million | $1.425 billion |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 1.08 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 09/03/2021 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | QSML | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 81 | 94 |
Median incremental investment | $620.00 | $1,000.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,413.72 | $4,907.20 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | QSML | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | QSML |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |